CALGB C80802 - PHASE III RANDOMIZED STUDY OF SORAFENIB PLUS DOXORUBICIN VERSUS SORAFENIB IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA (HCC)
Digestive System Cancer
This is a clinical trial of sorafenib that will be administered by mouth, which is investigational and doxorubicin that will be administered by IV and is standard of care.
IRB Protocol #
DAVID SHENEMAN at (720)848-0286 or DAVID.SHENEMAN@UCDENVER.EDU
ST. MARYS HOSPITAL - G.J. University of Colorado Hospital Valley View Hospital ST. MARYS HOSPITAL - G.J. University of Colorado Hospital Valley View Hospital
Eligibility and Other Participant Information
What To Expect : A screening period to determine eligibility. A treatment period(s) that can last up to 3 years. A follow up period will consist of clinic visit // Eligibility criteria include but are not limited to 18 years or older with advanced primary liver cancer.Eligibility criteria include but are not limited to 18 years or older with advanced primary liver cancer.